Medicare Part D coverage · tretinoin · RxCUI 208330
tretinoin 0.5 MG/ML Topical Cream [Retin-A]
Per the CMS 2026 Part D formulary file, tretinoin 0.5 MG/ML Topical Cream [Retin-A] is covered by 117 Medicare Part D plans (2.3% of enrollable products), averaging Tier 1.7, with prior authorization required on 66.7% of covering formularies.
- 2.3%
- Plan coverage
- 117
- Plans covering
- T1.7
- Avg tier
- 66.7%
- Prior auth required
What the CMS Formulary Data Shows for tretinoin 0.5 MG/ML Topical Cream [Retin-A]
Per the CMS 2026 Part D formulary file, tretinoin 0.5 MG/ML Topical Cream [Retin-A] (RxNorm concept RXCUI 208330, generic name tretinoin) appears on 3 distinct formulary files spanning 117 Medicare Part D plan offerings - 2.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 2, with a cross-plan average of Tier 1.7.
Real-world access to tretinoin 0.5 MG/ML Topical Cream [Retin-A] depends on utilization management as much as tier placement: 66.7% of covering formularies require prior authorization. 0% require step therapy. 33.3% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 91,688 Part D beneficiaries filled tretinoin 0.5 MG/ML Topical Cream [Retin-A] in 2023, with total plan-and-beneficiary spending of $22,910,407 and an average per-beneficiary annual cost of $249.87. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry tretinoin 0.5 MG/ML Topical Cream [Retin-A] today.
Coverage Details
- Formularies covering
- 3
- Plans covering
- 117
- Coverage rate
- 2.3%
- Tier range
- Tier 1 – Tier 2
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 66.7% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 33.3% of formularies
2023 Medicare Spending
- Beneficiaries
- 91,688
- Total spending
- $22,910,407
- Avg per beneficiary
- $249.87
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering tretinoin 0.5 MG/ML Topical Cream [Retin-A]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is tretinoin 0.5 MG/ML Topical Cream [Retin-A] covered by Medicare Part D?
Yes, tretinoin 0.5 MG/ML Topical Cream [Retin-A] is covered by 117 Medicare Part D plans (2.3% of all Part D formularies).
What tier is tretinoin 0.5 MG/ML Topical Cream [Retin-A] on Medicare Part D plans?
tretinoin 0.5 MG/ML Topical Cream [Retin-A] averages Tier 1.7 across Part D plans, ranging from Tier 1 to Tier 2.
Does tretinoin 0.5 MG/ML Topical Cream [Retin-A] require prior authorization?
66.7% of Part D formularies require prior authorization for tretinoin 0.5 MG/ML Topical Cream [Retin-A]. Step therapy: 0%. Quantity limits: 33.3%.
How much does Medicare spend on tretinoin 0.5 MG/ML Topical Cream [Retin-A]?
In 2023, total Medicare Part D spending on tretinoin 0.5 MG/ML Topical Cream [Retin-A] was $22,910,407, covering 91,688 beneficiaries. The average spend per beneficiary was $249.87.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- cilostazol 100 MG Oral Tablet T1.7
- dorzolamide 20 MG/ML Ophthalmic Solution T1.7
- erythromycin 0.005 MG/MG Ophthalmic Ointment T1.7
- zolpidem tartrate 10 MG Oral Tablet T1.7
- diclofenac sodium 75 MG Delayed Release Oral Tablet T1.7
- amiloride hydrochloride 5 MG / hydrochlorothiazide 50 MG Oral Tablet T1.7
Similar prior-authorization rate
- 0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita] 66.7% PA
- 0.4 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita] 66.7% PA
- 0.8 ML adalimumab-atto 100 MG/ML Auto-Injector [Amjevita] 66.7% PA
- nitisinone 4 MG/ML Oral Suspension [Orfadin] 66.7% PA
- 0.6 ML methylnaltrexone bromide 20 MG/ML Injection [Relistor] 66.7% PA
- delafloxacin 450 MG Oral Tablet [Baxdela] 66.7% PA